In an Australian study published in EClinicalMedicine, researchers evaluated the impact of a combined genomic screening program for hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia in young adults. The program proved to be cost-effective, reducing healthcare costs and averting numerous health events, while emphasizing the need for further optimization and equitable access within public healthcare systems.
Glass House Q1 Revenue Pulls Back 10% From Q4
Glass House Brands Reports First Quarter 2023 Financial Results Achieved Positive Free Cash Flow1 Narrowed Adjusted EBITDA2 loss to $0.1 million versus $2.6 million loss in Q4 Revenue of $29.0M, up